Invisalign: how patents, vertical integration, and litigation built a dental monopoly

Executive overview

Invisalign turned a $25B orthodontic market — dominated by cheap wire brackets and low-tech dentistry — into a software and manufacturing business with 75%+ gross margins. By patenting computer-aided tooth movement and building proprietary 3D printing at scale, Align Technologies locked up 90–95% of the clear aligner market for over two decades.

The core advantage was never just the plastic tray — it was owning the full stack: scan (iTero), design (Costa Rica treatment planning), manufacture (Juarez facility), and distribution (direct sales force). Patents bought time; vertical integration built the moat.

Incumbents almost always underestimate how much the software and data flywheel compounds — Invisalign's 2017 patent expiry changed almost nothing because competitors were decades behind on case data and treatment planning software.

What Invisalign actually sells

• Three product lines: clear aligners (Invisalign), intraoral scanner (iTero), and dental CAD software (exocad)
• Over 2M annual case starts in 2021, growing 20–30%+ per year
• Ships to 100,000+ doctors globally; orthodontists are ~60% of case volume
• Market still only ~20% penetrated — most orthodontists do 20–30% of cases with clear aligners
• Clear aligners can clinically handle 90%+ of all orthodontic cases today; the historical barrier is now gone

The economics across the value chain

• Wire brackets: ~$200–300 cost of goods to the practice, sold to consumer for $5,000–6,000
• Invisalign charges doctors $1,200–2,000 per case; consumer pays ~$5,500–6,000
• Align's cost to manufacture a full case: ~$250–300 fully loaded (trays at ~$3 each)
• Align gross margin: 73–77%; EBITDA margin: 25–30%
• Top orthodontic practices post 40–50% EBITDA margins using Invisalign exclusively
• Fewer office visits (6–12 vs. 20–40 for wire brackets) means higher throughput per chair

How they built the moat

• Computer-aided design patent (filed late 1990s) blocked all meaningful competitors until 2017
• Built their own direct sales force rather than using distributors like Henry Schein or Patterson
• Acquired Cadent (intraoral scanner) → rebranded as iTero; scans feed directly into Align's treatment planning system
• Established a digital treatment planning centre in Costa Rica (now also China, Spain, Germany)
• Built the world's largest 3D printing operation in Juarez, Mexico; cost per tray fell from $10–12 to sub-$3
• 400+ patents used actively as litigation weapons — sued SmileDirect Club, settled with Ormco/Invista for a 10% equity stake

Litigation as a competitive strategy

• Ormco (Danaher subsidiary, now Invista) sued Invisalign pre-2017; settled in 2009 — Ormco received 10% of Align when the stock was at ~$10–12 (Align later approached $50B market cap)
• Invisalign sued SmileDirect Club for an ownership stake; was countersued and lost the position before SDC's IPO
• Invisalign experimented with retail locations; litigation with SDC forced them to close
• The litigation posture deters competitors and forces them to design around Align's patent portfolio

Share of chair — the growth flywheel

• Share of chair: the percentage of a practice's case starts using one product
• Current average: 20–30% for Invisalign in a typical ortho practice
• Theoretical ceiling: 90–100% of cases; some practices already at 100%
• Growing share of chair from 20% to 40% would roughly double Align's revenue from existing doctors
• Clear aligners enable fewer office visits → more patients → higher practice EBITDA → reinvestment in growth

Growth vectors and risks

Bull case drivers:

• International under-penetration: China estimated at 1% penetration; 10–30M+ potential annual case starts
• Latin America and other emerging markets follow as per-capita GDP rises
• Deeper GP dentist penetration (currently limited by case complexity and training)
• Share of chair growth from 20% toward 50%+ as generational turnover in orthodontics accelerates
• Corporate dental groups (20–25% of practices) actively pushing to 100% clear aligner

Bear case — what halves the valuation:

• A competitor with better software and lower-cost automated manufacturing captures pricing
• Invista (formerly Ormco) already at double-digit % share of clear aligner starts in North American ortho — the credible near-term threat
• Direct 3D printing of aligners (no thermoforming mold step) could let any orthodontist print in-chair at a fraction of the cost
• Loyalty program dependency: doctors on volume discounts have high switching costs but are price-sensitive

Key structural dynamics

• Dental is an ~$800B global market; largely cash-pay, historically outside mainstream healthcare
• US braces market: ~$25B, projected to double in 10–15 years
• 12M orthodontic case starts globally; growing double digits annually
• Three market segments emerging: premium (Invisalign), mid-market (Candid), direct-to-consumer (SmileDirect Club) — each growing a different part of the total addressable market
• The right analogy is Apple vs. Android: SDC created a new low-end market rather than cannibalising Invisalign

Lessons from the Invisalign story

• For builders: Don't cap your market size assumptions — Invisalign could reach $10–30B revenue without owning half the global market
• For investors: Don't short a compounding healthcare business without deeply understanding the consumer and the clinical data; the 2017 patent-cliff thesis burned most who bet against Align
• IP strategy in medical devices is categorically different from software — patents are worth defending aggressively